Human metapneumovirus: a new respiratory pathogen

S Broor*, P Bharaj and H S Chahar
Department of Microbiology, All India Institute of Medical Sciences, New Delhi 110 029, India
*Corresponding author (Fax, 91-11-26588663; Email, shobha.broor@gmail.com)

Human metapneumovirus is a recently recognized pathogen of acute respiratory tract infection (ARI) in children as well as elderly and immunocompromised adults. The virus belongs to the family Paramyxoviridae, sub family Pneumovirinae and genus Metapneumovirus. Through genetic analysis it has been characterized into two groups A and B which are further divided into four sub-lineages. The virus is difficult to grow in tissue culture and hence reverse transcriptase-polymerase chain reaction (RT-PCR) for N and L gene is the method of choice for diagnosis. The virus has been seen in all countries with seasonal distribution in winter months for temperate and spring/summer for tropical countries. F gene is the most conserved among different lineages and efforts are underway to design recombination vaccine using F gene.

[Broor S, Bharaj P and Chahar H S 2008 Human metapneumovirus: a new respiratory pathogen; J. Biosci. 33 483–493]

1. Introduction

Acute respiratory tract infections (ARI) are a leading cause of morbidity and mortality worldwide (Denny and Loda 1986; Hijazi et al 1996). Of the 10 million deaths of children less than 5 years of age throughout the world 1·9 million children died from acute lower respiratory tract infections (ALRI) in the year 2000, 70% of them in sub-Sahara Africa and South Asia (Williams et al 2002). Although the incidence rates of ARI are almost similar in both developed and developing countries, the mortality is higher in developing countries (Shapiro 1998). The risk of pneumonia is 3-6 times higher in children from developing countries (10-20%) as compared to developed countries (3–4%) (Victora et al 1999).

Approximately 0.5 million children die due to ALRI in India each year, accounting for one fourth of the 1.9 million global ALRI deaths (Reddaiah and Kapoor 1988; Ahmad et al 2000; Williams et al 2002).

All classes of micro organisms including viruses, bacteria and protozoa are capable of infecting the respiratory tract, but viruses and bacteria are the common pathogens. A variety of viruses, including, respiratory syncytial virus (RSV), influenza viruses, parainfluenza viruses, adenoviruses, coronavirus and picornaviruses, are associated with different respiratory syndromes in all age groups (Grondahl et al 1999; Weigl et al 2000). However, despite extensive diagnostic testing, a substantial portion of respiratory tract infections still cannot be attributed to any known pathogens. In about a third cases of ALRI (Liolios et al 2001) and a half of upper respiratory tract infections (URI) (Nokso-Koivisto et al 2002) no pathogen could be detected. These observations suggest that unknown pathogens may be responsible for a substantial proportion of respiratory tract disease.

Metapneumovirus is a recently discovered etiological agent of acute respiratory illness (ARI). It was first reported in 2001 from The Netherlands from nasopharyngeal aspirates (taken over a 20 year period) in 28 hospitalized children and infants with ARI having signs and symptoms similar to that of RSV infection (van den Hoogen et al 2001). The virus was found to be closely related to the avian pneumovirus, a member of the Metapneumovirus genus, and was called

Keywords. Acute respiratory infections; human metapneumovirus

Abbreviations used: ALRI, acute lower respiratory tract infection; APV, avian pneumoviruses; ARI, acute respiratory tract infection; CPE, cytopathic effect; hMPV, human metapneumovirus; RSV, respiratory syncytial virus; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS, severe acute respiratory syndrome; SH, small hydrophobic
human metapneumovirus (hMPV) (van den Hoogen et al 2002). Although the virus was not isolated until recently, antibodies to the virus have been shown to be present in all persons ≥ 8 years of age in serum samples collected since 1958 (van den Hoogen et al 2001). Thus the virus is not a newly emerging pathogen and did not recently "jump" to the human population from an animal reservoir.

2. Virological characteristics

Genetic analysis of the virus showed that it is an RNA virus of the Paramyxoviridae family and Pneumovirinae subfamily along with RSV. The avian pneumoviruses (APV) (formerly turkey rhinotracheitis virus) is highly related to hMPV and these two viruses have been separated by taxonomists into a separate genus, Metapneumovirus (Lamb et al 2000).

Initial electron microscopic examination revealed that the viral isolate had morphology similar to paramyxoviruses. Spherical enveloped particles have a mean diameter of ~200 nm. In addition, filamentous and pleomorphic particles are also present. The virion is surrounded by a lipid envelope derived from the plasma membrane of the host cell into which the three virus glycoproteins, the attachment (G), fusion (F), and small hydrophobic (SH) proteins, are inserted (Collins and Mottet 1993). The RNA genome associates with viral proteins to form the helical nucleocapsid (represented on the right and in the centre of the virion on the left in figure 1). The proteins consist of the nucleocapsid protein (N), the phosphoprotein (P), and the large polymerase (L) protein. The M2-1 transcriptional enhancer protein is also thought to be associated with the nucleocapsid. The nucleocapsid is surrounded by the matrix (M) protein, which forms a link between the nucleocapsid and the lipid membrane of the virus particle (Easton et al 2004).

3. Genome organization

Full length sequences of at least 4 hMPV genomes have been reported (van den Hoogan et al 2002; Biacchesi et al 2003; Herfst et al 2004). The negative sense non-segmented RNA genome of the virus is about 13 kb in length (Easton et al 2004). The hMPV genome is predicted to encode 9 proteins in the order 3-N-PM- F-M2-SH-G-L-5 (the M2 gene is predicted to encode 2 proteins, M2-1 and M2-2, using overlapping open reading frames, as in RSV) (van den Hoogan et al 2002) (figure 2). The genome also contains noncoding 3'leader which has the viral promoter, 5' trailer and intergenic regions, consistent with the organization of RSV (Herfst et al 2004). However there are some differences in the genome of APV/hMPV as compared to RSV, they lack the 2 nonstructural proteins NS1 and NS2.

Figure 1. Schematic diagram of the pneumovirus particle (from Easton et al 2004).
located at the 3’ end of RSV genomes. These proteins counteract host interferons; therefore the lack of these genes in the metapneumoviruses may have important implications for the relative pathogenicity of these viruses compared with RSV strains (Collins et al 2001). Sequence identity between APV and hMPV open reading frames is 56% to 88% (van den Hoogen et al 2002).

Although the function of each of the gene products has not been formally tested, it is likely that the function of the proteins can be predicted by comparison with other paramyxoviruses. The F (fusion), G (glycosylated) and SH (short hydrophobic) proteins are integral membrane proteins on the surface of infected cells and virion particles. The F protein appears to be a classic viral fusion protein, with a predicted nonfurin F1/F2 cleavage site near a hydrophobic fusion peptide and 2 heptad repeats in the extra cellular domain that facilitate membrane fusion. The predicted G protein of hMPV exhibits the basic features of a glycosylated type II mucin-like protein but interestingly lacks the cluster of conserved cysteines sometimes termed the “cysteine noose” that is found in the RSV and APV G proteins. G gene of hMPV tends to be highly variable like RSV G gene which may be due to host immune selection pressure (Crowe 2004). The function of the SH proteins of both the viruses remains unknown. The N (nucleoprotein), P (phosphoprotein) and L (large, polymerase) proteins are replication proteins in the nucleocapsid, the M2-1 and M2-2 proteins are regulatory proteins and the M (matrix) protein may coordinate viral assembly of viral nucleocapsids with envelope proteins (Crowe 2004).

4. Genetic and antigenic diversity

The classification and naming of serotypes/serogroups, genotypes, subgroups, strains, variants and isolates of hMPV is still evolving. Based on genomic sequence and phylogenetic analysis, there are two major genotypes of hMPV, designated A and B (Biacchesi et al 2003; van den Hoogen et al 2003). These analyses are based on sequencing of the N, M, F, G, or L gene, and the genotype groupings are concordant regardless of which gene is studied (Bastein et al 2003; Biacchesi et al 2003; Boivin et al 2004; Peret et al 2004). Full length sequences of genomes from viruses representing the 2 major subgroups show that the diversity between hMPV subgroup A and B sequences is greatest for the SH and G proteins (59 and 37% identity, respectively), (van den Hoogen et al 2002; Biacchesi et al 2003; Herfst et al 2004) and is more than RSV subgroup A and B. hMPV F protein, which is predicted to be the principal target of protective antibodies, is more conserved in hMPV strains than RSV. The overall level of genome nucleotide sequence identity and aggregate proteome amino acid sequence identity between the two hMPV subgroups were 80 and 90%, respectively, similar to the respective values for RSV A and B groups (Hamelin et al 2004).

Based on the sequence analysis of two surface glycoprotein encoding genes namely F and G genes each of the major lineages are further subdivided into two genetic sub-lineages known as A1, A2 and B1, B2, the significance of this diversity is unclear at this time (Boivin et al 2004; van den Hoogen et al 2004) (figure 3). In a recent report Huck and colleagues have reported a new sub lineage within the A lineage. Previously reported A2 lineage is found to consist of two clusters namely, A2a and A2b. Among all the sub-lineages of hMPV the A2 sub-lineage shows the greatest diversity (Huck et al 2006).

The genetic diversity in hMPV strains also affects antigenic diversity, but to what extent has not been resolved. Studies with experimental infection of animals have suggested that the two lineages exhibited 48% antigenic relatedness based on reciprocal cross-neutralization assay with post-infection hamster sera (Skadopoulos et al 2004). However cross protection studies in hamsters and nonhuman primates have shown that each strain provided a high level of resistance to reinfection with the homologous or heterologous strain, supporting the conclusion that the two hMPV genetic lineages are highly related antigenically and are not distinct antigenic subtypes or subgroups (Herfst et al 2004; Skadopoulos et al 2004; van den Hoogen et al 2004). hMPV F protein is a major antigenic determinant that mediates extensive cross-lineage neutralization and protection (MacPhail et al 2004; Skadopoulos et al 2004). The extent of cross-protection in rodents cannot be extrapolated directly to the human situation because the animals are only semi permissive hosts for hMPV replication. Although difficult to assess, the extent of cross-protection is important to estimate because vaccine developers will choose to develop either a monovalent or a bivalent vaccine formulation based on this factor.

5. Clinical features of infection

hMPV has been associated with ARI in all age groups, with more severe diseases occurring in young children, elderly individuals and immunocompromised hosts.
Figure 3. Phylogenetic trees constructed based on the (A) partial F gene (Open reading frame [ORF] position 780–1,221) or (B) the complete G coding region (start G ORF to start L ORF). Trees were generated by maximum likelihood analysis using 100 bootstrap values. The four prototype viruses are shown in boldface, with ovals drawn around them (from van den Hoogan et al 2004).
The virus causes a variety of clinical syndromes in children that are typical of the paramyxoviruses, including upper and lower respiratory tract illnesses. The clinical characteristics of hMPV infections are not distinctive, thus, differentiating it from other respiratory viruses on clinical grounds is not possible (Stockton et al. 2002). A study conducted at Vanderbilt University Medical Center on the association of the virus in a cohort of 2000 subjects of age 0–5 years, followed during a 25-year period revealed that hMPV was associated with common cold (complicated by otitis media in one third), bronchiolitis, pneumonia, croup and exacerbation of reactive airway disease (Williams et al. 2004). The clinical profile of illness caused by hMPV was similar to that caused by RSV. In outpatients with ALRI, hMPV was detected in 12% of cases, which was second only to RSV (Williams et al. 2004). Hoarseness has also been observed more frequently in hMPV infection as compared to RSV (Falsey et al. 2003). Further compared with RSV infections, the children who develop hMPV infection are somewhat older, and the severity of disease is usually somewhat less than RSV (Boivin et al. 2003; Peiris et al. 2003; van den Hoogan et al. 2003; Viazov et al. 2003).

Human MPV infection is not restricted to the very young children but also occurs in adults and elderly subjects. In adults it usually causes flu like illness and colds (Boivin et al. 2002). In fragile elderly hMPV causes more severe disease than in healthy elderly or young adults (Falsey et al. 2003). In a study among 10 elderly of > 65 years of age who had underlying illness, 4 developed pneumonitis and 2 died due to hMPV infection (Boivin et al. 2002).

Immune status of infected subjects is also important in determining the severity of illness. hMPV infection has been reported in immunocompromised individuals. In 3 patients with acute lymphoblastic leukemia who had ALRI, hMPV was the sole pathogen detected and one of them died (Pelletier et al. 2002). hMPV infection has also been reported in HIV infected children but it is not clear if the severity of illness is more in this group (Madhi et al. 2003).

Respiratory virus infections are often associated with recurrent wheezing in children and exacerbations of asthma in older patients. Acute wheezing and asthma exacerbations have been associated with hMPV infection in some studies (Jarti et al. 2002; Peiris et al. 2003) but all studies have not shown this association (Rawlinson et al. 2003). In some studies in children with asthma hMPV was found more frequently than RSV (Peiris et al. 2003; van den Hoogen et al. 2003).

A study by Vicente et al. (2006) suggested that hMPV genotype A might be more pathogenic than genotype B, causing greater clinical severity in children whereas no differences in disease severity associated with either genotype (Agapov et al. 2006) was observed in another study.

6. Co-infections

Because the seasonal distributions of hMPV and RSV overlap, the potential for dual infection exists. Several studies have found hMPV –RSV co-infection rate of approximately 5-10% (Esper et al. 2004; Viazov et al. 2003; Williams et al. 2004; Xepapadaki et al. 2004). However, Greensill et al. (2003) reported that 70% of RSV-infected children who required intensive care in Liverpool, United Kingdom, were co-infected with hMPV, suggesting that dual infection with RSV and hMPV may predispose for severe infection particularly in otherwise healthy children. In another study from the United Kingdom, hMPV and RSV co-infection conferred an increased risk of admission to the pediatric intensive care unit (Semple et al. 2005). However, such synergistic association has not been found in other, population-based and case-control studies of hospitalized children (Boivin et al. 2003; Esper et al. 2003; Maggi et al. 2003). The possible synergistic interaction between hMPV and the severe acute respiratory syndrome (SARS) coronavirus has been recently postulated during the 2003 SARS outbreak in Canada and Hong Kong as many individuals were found to have co-infection with hMPV (Chan and Li 2003; Poutanen et al. 2003). On the other hand, such synergy between hMPV and SARS was not confirmed in experimental macaque models (Fouchier et al. 2003). In one case report, in an infant who had SARS, fatal encephalitis was correlated with hMPV infection as hMPV RNA was detected post-mortem in brain and lung tissue (Schilgen et al. 2005).

7. Re-infections

Cases of severe hMPV infections in adults (Boivin et al. 2002) and reinfection in immunocompromised subjects (Pelletier et al. 2002) suggest that, despite the universal infection in childhood, new infections can occur throughout life due to incompletely protective immune responses and/or acquisition of new genotype. Since severe disease is seen mainly in pediatric patients, it suggests that naturally acquired infection induces partial protection against the disease. However, it should be emphasized that there is no cross – protection among the virus strains. A recent report has described a child who suffered from two episodes of hMPV infection during a one month period, each caused by a different strain (Vargas et al. 2004).

8. Pathogenesis

The conventional model of attachment for the members of subfamily Pneumovirinae including genus Pneumovirus and Metapneumovirus involves the interaction of viral
G protein with a molecule or molecules on the host cell surface (Levine et al 1987). While the precise nature of the cellular receptor and mechanism of entry has not been identified, current evidence suggests that one or more cellular glycosaminoglycans or heparin-like molecules are involved in virus attachment and entry (Feldman et al 2000). Following G-protein-mediated attachment, the F glycoprotein promotes pH-independent fusion between the cell membrane and the virus envelope. For the F protein to become functional, it has to be cleaved by cellular proteases, and the hydrophobic amino terminal region of the F1 component then promotes the fusion process, which introduces the internal components of the virion into the cytoplasm of the host cell, where the remainder of the infectious cycle takes place. Recent experimental work using primates (chimpanzees, cynomolgus and rhesus macaques, African green monkeys) and small animals (hamsters, cotton rats, mice and ferrets) has been performed to characterize the pathogenesis associated with this viral infection; hMPV replicates to a various extent in the upper respiratory tract of these experimental animals, although clinical symptoms after intranasal challenge have only been observed in chimpanzees, Cynomolgus macaques and BALB/c mice so far (van den Hoogen et al 2001; Alvarez et al 2004; Kuiken et al 2004; Skiadopoulos et al 2004; Hamelin et al 2005). In BALB/c mice and cotton rats, time course studies have indicated that peak viral titers are found around day 4-5 after infection and decrease thereafter Alvarez et al (2004a) and Hamelin et al (2005), have demonstrated that hMPV may present an initial biphasic replication pattern in lungs of BALB/c mice, with hMPV RNA still detectable more than 180 days after infection. Such persistence could be explained by an aberrant T helper cell type 2-like immune response, with impaired virus clearance after primary hMPV infection (Alvarez and Tripp 2005).

Significant pulmonary inflammatory changes have been found in BALB/c mice and cotton rats (Alvarez et al 2004; Hamelin et al 2005). Interestingly significant inflammatory changes were still present in the cotton rat animal model more than 21 days after viral challenge (Hamelin et al 2005). Increase in many cytokines and chemokines such as interleukin IL-2, IL-8, IL-4, INF-γ, macrophage inflammatory protein 1α and monocyte chemotactic protein has been observed in the lungs or bronchoalveolar lavage of both mice and cotton rats in response to hMPV challenge (Alvarez et al 2004, Hamelin et al 2005). In humans, hMPV infection has also been associated with an increase of IL-8 in upper respiratory tract secretions and with chronic inflammatory changes of the airways, with presence of, intra alveolar foamy and hemosiderin-laden macrophages (Laham et al 2004, Vargas et al 2004). When compared with RSV, hMPV infections in humans seem to induce lower levels of inflammatory cytokines such as IL-12, tumor necrosis factor α, IL-6 and IL-1β (Laham et al 2004). Thus far, no experimental human volunteer studies have been reported.

9. Epidemiology

Since its initial description in 2001, hMPV has been isolated from individuals of all ages with ARI, and has been identified in every continent. hMPV infections have been documented in Europe [United Kingdom (Stockton et al 2002), Finland (Jartti et al 2002), Italy (Maggi et al 2003), France (Freymuth et al 2003), Germany (Viazov et al 2003), Spain (Vicente et al 2003), Norway (Dollner et al 2004)]; America, Canada (Boivin et al 2002), United States (Esper et al 2003, Falsey et al 2003), Brazil (Cuevas et al 2003) Australia (Nissen et al 2002), Asia [Hong Kong (Peiris et al 2003), Japan (Ebihara et al 2004), Korea (Kim and Lee 2005) Thailand (Samransamruajkit et al 2005)] and Africa [Yemen, (Al-Sonboli et al 2005), South Africa (Ludewick et al 2005)]. In a preliminary study from Pune in India hPMV was found in 5 of 26 children with ARI (Rao et al 2004). In a study of children seen in a large referral hospital in Delhi hMPV was detected in 12% of ARI cases by reverse transcriptase-polymerase chain reaction (RT-PCR) (Banerjee et al 2007).

Role of hMPV in ARI has been evaluated in many studies mostly using molecular methods. In young hospitalized children hMPV has been detected in 5-10% of ARI cases. (Peret et al 2002; Bastein et al 2003; Bovin et al 2003; Esper et al 2003, 2004; McIntosh and McAdam 2004). However in one study from Italy the rates of hospitalizations due to hMPV infection varied from 7-43% (Maggi et al 2003). The rates of detection of hMPV in adults are usually lower than children with rates of about 3% in general community (Stockton et al 2002). It is interesting to note that detection rates of hMPV have generally been higher in retrospective studies than in prospective studies, an observation consistent with a degree of selection bias. This indicates that large prospective studies are needed in order to clarify the role of hMPV in various clinical conditions (Hamelin et al 2004).

Most hMPV infections occur in < 5 years of age, with children <2 years of age being most at risk for serious hMPV infections. In one study the peak was seen at 4–6 months of age (van den Hoogen et al 2004). However, hMPV infections tend to occur in slightly older children compared to RSV (Peiris et al 2003; van den Hoogen et al 2003).

The activity of hMPV in temperate climates peaks between December and February (Maggi et al 2003; van den Hoogen et al 2003) where as in subtropics it peaks in spring-summer (Peiris et al 2003). The peak of activity of hMPV at any given location often coincides with or follows the peak of RSV activity (Boivin et al 2003; Esper et al 2004).
Outbreaks of hMPV are to be a local phenomenon unlike influenza virus, where two or three strains spread across the globe each year. Strains of hMPV differ from community to community, and strains identified in one location may be quite similar to strains identified in other locations in different years. For example, the prototype strain identified in The Netherlands is genetically similar to strains identified in Australia; New Haven, Connecticut and Quebec, Canada in different years (Esper et al. 2006). We in Delhi also found that 2 lineages of hMPV circulated during the same season i.e. in 2005-06 A2b and B1 lineages were seen with A2b being the predominant genotype where as in 2006-07 B1 and B2 were found to co-circulate with predominance of B1 (Broor S, et al, unpublished data).

Although formal transmissions studied have not been carried out, transmission most likely is through large particle respiratory secretions and fomites as is true for RSV (Human Metapneumovirus 2006). Nosocomial transmission has been reported in hospital setting (Pieris et al 2003).

9.1 Seroepidemiology

Presence of hMPV antibodies in serum samples obtained in 1958 showed that the virus has been circulating for at least for the past 50 years in The Netherlands (van den Hoogen et al 2001). By the age of 5 years, >90% of individuals screened have evidence of hMPV infection. The seroprevalence of hMPV specific antibody in adults is nearly 100% (van den Hoogen et al 2001, Leung et al 2005). The hMPV-specific antibodies in infants <3 months of age has been detected in >90% of the cases tested, indicating that maternally derived antibodies are present in young children (Leung et al 2005). Whether these hMPV specific antibodies protects against infection or lessens the severity of illness is not known.

10. Diagnosis

10.1 Virus isolation

hMPV replicates poorly in conventional cell culture and is relatively difficult to isolate. Many strains show reliable cytopathic effect (CPE) in tertiary monkey kidney cell line/LLCMK-2 cells (Peret et al 2002). The CPE is quite variable, some strains show syncytia formation and other only produce rounding (Bovin et al 2002). CPE is usually observed after 10-21 days (mean 17 days). Confirmation of CPE is done by RT-PCR or indirect immunofluorescence staining using hMPV specific antibodies.

Recent reports have shown that hMPV can replicate efficiently in Hep-2 cells but does not produce good CPE. van den Hoogen et al (2004) reported that Vero cell clone 118 is permissible for expression of virus from all four lineages and CPE is easier to observe. Many laboratories are now using this cell line for routine virus isolation (van den Hoogen et al 2004). In addition shell vial culture for rapid isolation of hMPV has also been described (Reina et al 2007). They showed that shell vial culture using commercial LLCMK-2 cells should be a method for isolating hMPV from respiratory samples in pediatric population.

10.2 Direct immunofluorescence assay

Direct immunofluorescence assay (DFA) using virus specific antibodies is a rapid method to detect respiratory viruses and is commonly used in diagnostic laboratories. Commercially available hMPV specific antibodies have been developed for direct immunofluorescence assays, though this method may not be as sensitive as RT-PCR for the detection of hMPV (Ebihara et al 2005, Landry et al 2005, Percivalle et al 2005).

10.3 Molecular diagnostics

Because of the unavailability of rapid antigenic detection assays in the past and slow growth in tissue culture molecular methods have become the method of choice for the diagnosis of hMPV infection. Cote et al (2003) reported that primers that bind regions of the N and L genes are highly sensitive for the detection of hMPV strains of both genotypes. However, it is reported that the P gene of hMPV is an ideal target for the molecular detection and genotyping as P gene provides the conserved region for designing RT-PCR primers and adequate variability to permit the accurate genotyping of the virus into 2 main lineages and 4 sub-lineages (Mackay et al 2004).

Real time PCR has also been described for hMPV which allows amplification and quantitation of this pathogen in clinical samples. Real-time RT-PCR is a powerful method to detect hMPV and other respiratory viruses. The assay has been developed to detect the N gene of all known hMPV lineages (Maertzdorf et al 2004) and real time RT-PCR targeting the N and / or L gene is more sensitive, specific, and rapid method to detect this virus in clinical samples than conventional RT-PCR (Mackay et al 2003). Nucleic acid sequence based amplification assay (NASBA) targeting the M gene has also been developed for detection of hMPV infection in respiratory specimens (Dare et al 2007).

10.4 Serology

Enzyme-linked immunosorbent assay (ELISA) can also be used for hMPV serological testing using the hMPV-infected

J. Biosci. 33(4), November 2008
cells (Falsey et al 2003, Hamelin et al 2005). Recently, ELISA methods using viral N or F protein expressed in prokaryotic (Hamelin and Boivin 2005) or recombinant vesicular stomatitis virus (VSV) (Leung et al 2005) and recombinant baculovirus system (Liu et al 2007) have been developed to detect antibodies against hMPV. Use of these assays in sero-epidemiologic studies might be helpful for detection of antibody response against hMPV infections thus increasing the understanding of the human immune responses to hMPV and permitting better understanding of the epidemiology of this virus. However, since infections with hMPV are universal, serologic testing for diagnosis can only help if four fold increases in antibody titers or seroconversion is demonstrated (Prins and Wolthers 2004).

11. Vaccine candidates and animal models

The development of a safe and effective vaccine to protect against hMPV is a reasonable goal. Several promising vaccine candidates have been tested in animal models. A live recombinant human parainfluenza virus that contains the hMPV F gene has been shown to induce hMPV-specific antibodies and to protect experimental animals from hMPV challenge (Skiadopoulos et al 2004).

A chimeric bovine/human parainfluenza virus 3 expressing the hMPV F elicits neutralizing antibodies against both Parainfluenza virus and hMPV (Tang et al 2005). However, the results of these animal challenge studies should be interpreted cautiously. There are many limitations of the small-animal model for testing potential hMPV vaccines, not the least of which is that the pathogen is highly host restricted. The safety and efficacy of a recombinant hMPV vaccine may be difficult to predict. Chimeric hMPV/avian pneumovirus recombinant viruses in which the N or P gene of hMPV was replaced with the corresponding gene from avian pneumovirus are attenuated in African green monkeys (the P gene chimera is 10- to 1,000-fold more attenuated than the N chimera), though both are as immunogenic as wild-type hMPV (Pham et al 2005). This represents another strategy for the development of recombinant attenuated live hMPV vaccines.

12. Therapy

Other than influenza virus, antiviral therapy for respiratory viruses has not shown tremendous potential. It is unknown what role the host’s inflammatory response plays during hMPV disease. Nonetheless, antiviral compounds have been tested with hMPV.

The antiviral activity of ribavirin to inhibit the replication of hMPV is equivalent to that observed with RSV (Wyde et al 2003). Other compounds, such as NMSO3, a sulphated sialyl lipid that has been shown to have potent antiviral activity against RSV in tissue culture cells, have been shown to have anti-hMPV activity in vitro (Wyde et al 2004). It is likely that an hMPV-neutralizing monoclonal antibody for prophylaxis of high-risk infants (similar to the anti-RSV F humanized monoclonal antibody currently used for prevention of severe RSV disease) will be developed and tested. The progress towards an effective antiviral strategy for hMPV is currently limited by the scant data on pathogenesis of the virus in the natural host.

13. Conclusions

Since the discovery of hMPV in 2001, the virus has been identified worldwide. hMPV is a common respiratory pathogen, particularly in infants and young children. The virus is associated with both upper and lower respiratory tract infections and may be a trigger for asthma. There are two major genotypes of hMPV, whether these genotypes represent distinct serotypes re-mains controversial. The major challenges faced by the medical and scientific communities are: the understanding of the pathogenesis of hMPV disease and the development of a safe and effective vaccine to protect against infection and disease caused by this newly recognized respiratory virus.

References

Agapov E, Sumino K C, Gaudreault-Keener M, Storch G A and Holtzman M J 2006 Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness; J. Infect. Dis. 193 396–403

Ahmad O B, Lopez A D and Inoue M 2000 The decline in child mortality: a reappraisal; Bull. World Health Org. 78 1175–1191

Al-Sonboli N, Hart C A, Al-Aeryani A, Banajeh S M, Al-Aghbari N, Dove W and Cuevas L E 2005 Respiratory syncytial virus and human Metapneumovirus in children with acute respiratory infections in Yemen; Pediatr. Infect. Dis. J. 24 734–736

Alvarez R, Harrod K S, Shieh W J, Zaki S and Tripp R A 2004 Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies; J. Virol. 78 14003–14011

Alvarez R and Tripp R A 2005 The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice; J. Virol. 79 5971–5978

Banerjee S, Bharaj P, Sullender W, Kabra S K and Broor S 2007 Human Metapneumovirus infections among children with acute respiratory infections seen in a large referral hospital in India; J. Clin. Virol. 38 70–72

Bastein N, Normand S, Taylor T, Ward D, Peret T C, Boivin G, Anderson L J and Li Y 2003 Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains; Virus Res. 93 51–62
Metapneumovirus: a new respiratory pathogen

Biacchesi S, Skiadopoulos M H, Boivin G, Hanson C T, Murphy B R and Collins P L, Buchholz U J 2003 Genetic diversity between human metapneumovirus subgroups; Virology 315 1–9

Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, Peret T C, Erdman D D and Anderson L J 2002 Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups; J. Infect. Dis. 186 1330–1334

Boivin G, De Serres G, Cote S, Gilea R, Abed Y, Rochette L, Bergeron L G and Dery P 2003 Human metapneumovirus infections in hospitalized children; Emerg. Infect. Dis. 9 634–640

Boivin G, Mackay I, Sloots T P, Madhi S, Freymuth F, Wolf D, Shemer-Avni Y, Ludewick H, et al 2004 Global genetic diversity of human metapneumovirus fusion gene; Emerg. Infect. Dis. 10 1154–1157

Chan E and Li Y 2003 Human metapneumovirus infection in the Canadian population; J. Clin. Microbiol. 41 4642–4646

Collins P L and Mottet G 1992 Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin-A; J. Gen. Virol 73 849–863

Collins P L and Mottet G 1993 Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus; J. Gen. Virol. 74 1445–1450

Collins P L, Chanock R M and Murphy B R 2001 Respiratory Syncytial virus; in Fields virology 4th edition (eds) D M Knipe, P M Howley, D E Griffin, R A Lamb, M A Martin, B Roizman and S E Straus (Philadelphia, Lippincott-Raven Publishers) vol. 1, pp 1443–1485

Cote S, Abed Y and Boivin G 2003 Comparative evaluation of real-time PCR assays for detection of the human Metapneumovirus; J. Clin. Microbiol. 41 3631–3635

Crowe E J 2004 Human Metapneumovirus as a Major Cause of Human Respiratory Tract Disease; Pediatr. Infect. Dis. J. 23 S215–S221

Cuevas L E, Nasser A M, Dove W, Gurgel R Q, Greensill J and Hart C A 2003 Human metapneumovirus and respiratory syncytial virus, Brazil; Emerg. Infect. Dis. 9 1626–1628

Dare R, Sanghavi S, Bullotta A, Keightley M C, George K S, Wadowsky R M, Paterson D L, McCurry K R, et al 2007 Diagnosis of human metapneumovirus infection in immunosuppressed lung transplant recipients and children evaluated for pertussis; J. Clin. Microbiol. 45 548–552

Denny F W and Loda F A 1986 Acute respiratory infections are the leading cause of death in children in developing countries; Am. J. Trop. Med. Hyg. 35 1–2

Dollner H, Risnes K, Radke A and Nordbo S A 2004 Outbreak of Human metapneumovirus infection in Norwegian children; Pediatr. Infect. Dis. J. 23 436–440

Easton A J and Chambers P 1997 Nucleotide sequence of the genes encoding the matrix and small hydrophobic proteins of pneumonia virus of mice; Virus Res. 48 27–33

Easton A J, Domachowske J B and Rosenberg H F 2004 Animal pneumonia virus: molecular genetics and pathogenesis; Clin. Microbiol. Rev. 17 390–412

Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Hara M, Takahashi Y and Kobayashi K 2004 Human metapneumovirus infection in Japanese children; J. Clin. Microbiol. 42 126–132

Ebihara T, Endo R, Ma X, Ishiguro N and Kikuta H 2005 Detection of human metapneumovirus antigens in nasopharyngeal secretions by an immunofluorescent-antibody test; J. Clin. Microbiol. 43 1138–1141

Esper F, Boucher D, Weibel C, Martinello R A and Kahn J S 2003 Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children; Pediatrics 111 1407–1410

Esper F, Martinello R A, Boucher D, Weibel C, Ferguson D, Landry M L and Kahn J S 2004 A 1-year experience with human metapneumovirus in children aged -5 years; J. Infect. Dis. 189 1388–1396

Falsary A R, Erdman D D, Anderson L J and Walsh E E 2003 Human metapneumovirus infections in young and elderly adults; J. Infect. Dis. 187 785–790

Feldman S A, Audet A and Beeler J A 2000 The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate; J. Virol. 74 6442–6447

Foucher R A, Kuiken T, Schutten, M, van Amerongen G, van Doornum G J, van den Hoogen B G, Peiris M, Lim W, Stöhr K and Osterhaus A D 2003 Aetiology: Koch’s postulates fulfilled for SARS virus; Nature (London) 15 240

Freymuth F A, Vabret L, Legrand N, Ettaredossi F, Lafay-Delatoue J, Brouard and Guillois B 2003 Presence of the new human Metapneumovirus in French children with bronchiolitis; Pediatr. Infect. Dis. J. 22 92–94

Greensill J, McNamara P S, Dove W, Flanagan B, Smyth R L and Hart C A 2003 Human metapneumovirus in severe respiratory Syncytial virus bronchiolitis; Emerg. Infect. Dis. 9 372–375

Grondahl B, Puppe W, Hoppe A, Kuhne I, Weigl J A and Schmitt H J 1999 Rapid identification of nine micro-organisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study; J. Clin. Microbiol. 37 1–7

Hamelin M E, Abed Y and Boivin G 2004 Human metapneumovirus: a new player among respiratory viruses; Clin. Infect. Dis. 38 983–990

Hamelin M E and Boivin G 2005 Development and validation of an Enzyme-linked immunosorbent assay for human Metapneumovirus serology based on a recombinant viral protein; Clin. Diagn. Lab. Immunol. 12 249–253

Hamelin M E, Cote S, Laforge , Lampron N, Bourbeau J, Weiss K, Gilea R, DeSerres G and Boivin G 2005 Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease; Clin. Infect. Dis. 41 498–502

Herfst S, De Graaf M, Schickli J H, et al 2004 Recovery of human metapneumovirus genetic lineages A and B from cloned cDNA; J. Virol. 78 8264–8270

HiJazi Z, Pacsa A, Eisa S, el Shazli A and abd el-Salam R A 1996 Laboratory diagnosis of acute lower respiratory tract viral infections in children; J. Trop. Pediatr. 42 276–280

Huck B, Scharf G, Neumann-Heiñelin D, Puppe W, Weigl J and Falcone V 2006 Novel human metapneumovirus sublineage; Emerg. Infect. Dis. 12 147–150
Human Metapneumovirus 2006 Red Book 460–461
Jarti T, van den Hoogen B G, Garofalo R P, Osterhaus A D and Ruuskanen O 2002 Metapneumovirus and acute wheezing in children; Lancet 360 1393–1394
Kim Y K and Lee H J 2005 Human metapneumovirus-associated lower respiratory tract infections in korean infants and young children; Pediatr. Infect. Dis. J. 24 1111–1112
Kuijken T, van den Hoogen B G, van Riel D A, Laman J D, van Amerongen G, Sprong L, Fouchier R A and Osterhaus A D 2004 Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract; Am. J. Pathol. 164 1893–1900
Laham F R, Israele V, Casellas J M, Garcia A M, Lac Prugent C M, Hoffman S J, Hauer D, Thumar B, et al 2004 Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy; J. Infect. Dis. 189 2047–2056
Lamb R A, Collins P L, Kolakofsky D, Melero J A, Nagai Y, Oldstone M B A, et al 2000 Family paramyxoviridae; in Virus taxonomy (eds) M H V Van Regenmortel, C M Fauquet, D H L Bishop, K E Bean, S H Desselberger, O Grimes, J L McGeoch, A M Moreira, A M Nishioka, K J Perlman, M H Purdy, H A Seven, J M Studdert, S H Tiemeier, S V Telford, M J Wimmer and M M Zinserling; 5th edition; Washington, DC: International Committee on Taxonomy of Viruses; 2000: 190–196
Leung J, Esper F, Weibel C and Kahn J S 2005 Seroepidemiology of human metapneumovirus 2006; J. Gen. Virol. 85 1655–1663
Madhi S A, Ludewick H, Abed Y, Klugman K P and Boivin G 2003 Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants; Clin. Infect. Dis. 37 1705–1710
Maertzdorf J, Wang C K, Brown J B, Quinto J D, Chu M, de Graaf M, van den Hoogen B G, Spaete R, Osterhaus A D and Fouchier R A 2004 Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages; J. Clin. Microbiol. 42 981–986
Maggi F, Pifferi M, Vattoroni M, Fornai C, Tempestini E, Anzilotti S, Lanini L, Andreoli E, Ragazzo V, Pistello M, Specter S and Bendinelli M 2003 Human metapneumovirus associated with respiratory tract Infections in a 3 year study of nasal swabs from infants in Italy; J. Clin. Microbiol. 41 2987–2991
McIntosh K and McDermott A J 2004 Human Metapneumovirus – an important new respiratory virus; N. Engl. J. Med. 350 431–433
Nissen, M D, Siebert D J, Mackay I M, Sloots T P and Withers J S 2002 Evidence of human metapneumovirus in Australian children; Med. J. Aust. 176 188
Nokso-Koivisto J, Pitkaranta A, Blomqvist S, Jokinen J, Kleemola M, Takala A, Kilpi T and Hovi T 2002 Viral etiology of frequently recurring respiratory tract infections in children; Clin. Infect. Dis. 35 540–546
Peiris J S, Tang W H, Chan K H, Khong P L, Guan Y, Lau Y L and Chiu S S 2003 Children with respiratory disease associated with metapneumovirus in Hong Kong; Emerg. Infect. Dis. 9 628–633
Pelletier G, Dery P, Abed Y and Boivin G 2002 Respiratory tract reinfec tions by the new human metapneumovirus in an immunocompromised child; Emerg. Infect. Dis. 8 976–978
Percivalle E, Sarasini A, Visai L, Revello L G and Gerna G 2005 Rapid detection of human metapneumovirus strains in nasopharyngeal aspirates and shelf vial cultures by monoclonal antibodies; J. Clin. Microbiol. 43 3443–3446
Peret T C, Boivin G, Li Y, Couillard M, Humphrey C, Osterhaus A D, Erdman D D and Anderson L J 2002 Characterization of human metapneumoviruses isolated from patients in North America; J. Infect. Dis. 185 1660–1663
Peret T C, Abed Y, Anderson L J, Erdman D D and Boivin G 2004 Sequence polymorphism of the predicted human metapneumovirus G glycoprotein; J. Gen. Virol. 85 679–686
Pham Q N, Biacchesi S, Skaidopoulos M H, Murphy B R, Collins P L and Buchholz U J 2005 Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo; J. Virol. 79 15114–15122
Poutanen S M, Low D E, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, et al 2003 Identification of severe acute respiratory syndrome in Canada; N. Engl. J. Med. 348 1995–2005

J. Biosci. 33(4), November 2008
van den Hoogen B G, Bestebroer T M, Osterhaus A D and Fouchier R A 2003 Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients; *J. Infect. Dis.* **188** 1571–1577

van den Hoogen B G, Herfst S, Spong L, Cane P A, Forleo-Neto E, de Swart R L, Osterhaus A D and Fouchier R A 2004 Antigenic and genetic variability of human metapneumoviruses; *Emerg. Infect. Dis.* **10** 658–666

Vargas S O, Kozakewich H P, Perez-Atayde A R and McAdam A J 2004 Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus; *Pediatr. Dev. Pathol.* **7** 478–486

Viazov S, Ratjen F, Scheidhauer R, Fiedler M and Roggendorf M 2003 High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates; *J. Clin. Microbiol.* **41** 3043–3045

Vicente D, Cilla G, Montes M and Pérez-Trallero E 2003 Human metapneumovirus and community-acquired respiratory illness in children; *Emerg. Infect. Dis.* **9** 602–603

Vicente D, Montes M, Cilla G, Perez-Yarza E G and Perez-Trallero E 2006 Differences in clinical severity between genotype A and genotype B human metapneumovirus infection in children; *Clin. Infect. Dis.* **15** e111–e113

Victoria C G, Kirkwood B R, Ashworth A, Black R E, Rogers S, Sazawal S, Campbell H and Gove S 1999 Potential interventions for the prevention of childhood pneumonia in developing countries: improving nutrition; *Am. J. Clin. Nutr.* **70** 309–320

Weigl J A, Puppe W, Grondahl B and Schmitt H J 2000 Epidemiological investigation of nine respiratory pathogens in hospitalized children in Germany using multiplex reverse-transcriptase polymerase chain reaction; *Eur. J. Clin. Microbiol. Infect. Dis.* **19** 336–343

Williams J V, Harris P A, Tollefson S J, Halburnt-Rush L L, Pingsterhaus J M, Edwards K M, Wright P F and Crowe J E Jr 2004 Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children; *N. Engl. J. Med.* **350** 443–450

Williams B G, Gouws E, Boschi-Pinto C, Bryce J and Dye C 2002 Estimates of world wide distribution of child deaths from acute respiratory infections; *Lancet Infect. Dis.* **2** 25–32

Wyde P R, Myklet E H, Chetty E H, Jewell A M, Boivin G and Piedra P A 2003 Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro; *Antiviral Res.* **60** 51–59

Wyde P R, Moylett E H, Chetty E H, Jewell A M, Bowlin T L and Piedra P A 2004 Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays; *Antiviral Res.* **63** 51–59

Xepapadaki P, Psarras S, Bossios A, Tsiolias M, Gourgiotis D, Liapid-Adamidou G, Constantopoulos AG, Kafetzis D and Papadopoulos NG 2004 Human Metapneumovirus as a causative agent of acute bronchiolitis in infants; *J. Clin. Virol.* **30** 267–270